Bezafibrate
- Generic Name
- Bezafibrate
- Brand Names
- Bezalip
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20ClNO4
- CAS Number
- 41859-67-0
- Unique Ingredient Identifier
- Y9449Q51XH
- Background
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
- Indication
For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary ...
- Associated Conditions
- Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia, Primary Hypercholesterolemia, Type IIb hyperlipoproteinaemia
- Associated Therapies
- -
Study of OCA in Combination with BZF Evaluating Efficacy, Safety, and Tolerability in Participants with PBC
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Intercept Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT04594694
- Locations
- 🇬🇷
Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa, Larissa, Greece
🇫🇷Hôpital Henri Mondor, Créteil, France
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
PC-300 Tea Effect on Triglyceride Levels
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Ciprés Grupo Médico CGM SC
- Target Recruit Count
- 34
- Registration Number
- NCT03649269
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT02984982
- Locations
- 🇯🇵
Investigational Site Number 392008, Gifu-shi, Japan
🇯🇵Investigational Site Number 392022, Chiyoda-ku, Japan
🇯🇵Investigational Site Number 392039, Hiroshima-shi, Japan
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2018-04-23
- Target Recruit Count
- 34
- Registration Number
- NCT02937012
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
The Effect of Bezafibrate on Cholestatic Itch
- Conditions
- Interventions
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2016-03-08
- Target Recruit Count
- 84
- Registration Number
- NCT02701166
- Locations
- 🇳🇱
Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
🇳🇱Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
Bezafibrate Plus Berberine in Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 36
- Registration Number
- NCT02548832
- Locations
- 🇲🇽
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02481245
- Locations
- 🇺🇸
The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Bezafibrate in Mitochondrial Myopathy
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 6
- Registration Number
- NCT02398201
- Locations
- 🇬🇧
Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Target Recruit Count
- 100
- Registration Number
- NCT02291796
Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 100
- Registration Number
- NCT01654731
- Locations
- 🇫🇷
Hepatology department - Hopital Saint Antoine, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.